Blood tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and CA125, are currently the main tumor biomarkers for CRC, which play significant roles in CRC screening, diagnosis, and treatment monitoring. This evidence concerns the gene CEACAM5 and colorectal carcinoma.